Economic evaluation of ponatinib vs reference and generic imatinib in front-line management of philadelphia chromosome-positive acute lymphoblastic leukemia: A value dilemma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Acute lymphoblastic leukemia (ALL) mainly affects children, though it also occurs in adults. About 25% of adults with ALL have the more aggressive Philadelphia chromosome-positive (Ph+) subtype. Standard treatment includes tyrosine kinase inhibitors (TKIs) in combination with chemotherapy or corticosteroids, which have greatly enhanced survival rates over the past 2 decades. Ponatinib, a third-generation TKI demonstrated greater efficacy compared with imatinib, a first-generation TKI, in the PhALLCON trial. OBJECTIVE: To conduct an economic evaluation of ponatinib compared with (1) reference imatinib, (2) the average cost of several imatinib generics, and (3) the weighted cost of imatinib in adults with Ph+ ALL from the US payer perspective. METHODS: Cost-effectiveness and cost-utility analyses were performed using a partitioned survival model with 3 mutually exclusive health states: progression-free, progressed disease, and death. A time horizon of 60 months and a 3% discount rate were applied. The incremental costs per 1% gain in probability of progression-free survival and overall survival at 60 months were estimated. RESULTS: Life-years (LYs) and quality-adjusted LYs (QALYs) were higher for ponatinib (3.74, 2.15) than for imatinib (3.52, 1.68). Compared with reference imatinib, ponatinib was dominant, having cost savings of $56,024. Compared with average generic imatinib, ponatinib had an incremental cost of $147,147, yielding an incremental cost-effectiveness ratio (ICER) of $668,150 per LY gained and incremental cost-utility ratio (ICUR) of $314,646 per QALY gained. Compared with weighted imatinib, ponatinib had an incremental cost of $128,861, yielding ICER of $585,122 per LY gained and ICUR of $275,546 per QALY gained. The differential cost of ponatinib per patient for a 1% increase in the probability of remaining in the progression-free survival state was $6,883 in savings compared with reference imatinib, but an additional $18,077 compared with average generic imatinib and $15,835 compared with weighted imatinib. CONCLUSIONS: Ponatinib demonstrated cost savings relative to reference imatinib, though its incremental costs were substantially higher when compared with both average and weighted imatinib, for an approximate gain of 3 months of life and 6 months of quality-adjusted life. This presents a value dilemma: whether to save money with more affordable alternatives for a slightly lower clinical benefit, possibly parlaying these cost-efficiencies into expanded patient access. This highlights the challenge of balancing clinical benefits with economic sustainability, particularly when the modest health gains come at a substantially higher cost. Although ponatinib offers therapeutic value, payers and policymakers must carefully evaluate whether the clinical outcomes justify the additional costs, considering also its safety profile.